Overview Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis Status: Completed Trial end date: 2007-05-01 Target enrollment: Participant gender: Summary Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study. Phase: Phase 3 Details Lead Sponsor: Warner ChilcottCollaborator: SanofiTreatments: Etidronic AcidRisedronate SodiumRisedronic Acid